Journal Article
. 2019 Nov;21(1).
doi: 10.1186/s13058-019-1197-x.

High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy

Hyelin Na 1 Jinil Han 2 Na-Lee Ka 1 Min-Ho Lee 1 Yoon-La Choi 3 Young Kee Shin 4 Mi-Ock Lee 5 
  • PMID: 31779659
  •     24 References
  •     1 citations


Background: Nuclear receptor subfamily 1, group D, member 1 (NR1D1) is a ligand-regulated nuclear receptor and transcriptional factor. Although recent studies have implicated NR1D1 as a regulator of DNA repair and proliferation in breast cancers, its potential as a therapeutic target for breast cancer has not been assessed in terms of clinical outcomes. Thus, this study aims to analyze NR1D1 expression in breast cancer patients and to evaluate its potential prognostic value.

Methods: NR1D1 expression was analyzed by immunohistochemistry using an anti-NR1D1 antibody in 694 breast cancer samples. Survival analyses were performed using the Kaplan-Meier method with the log-rank test to investigate the association of NR1D1 expression with clinical outcome.

Results: One hundred thirty-nine of these samples exhibited high NR1D1 expression, mostly in the nucleus of breast cancer cells. NR1D1 expression correlated significantly with histological grade and estrogen receptor status. Overall survival (OS) and disease-free survival (DFS) did not correlate significantly with NR1D1 expression in breast cancer patients regardless of whether they had received chemotherapy. Subgroup analysis performed according to molecular subtype of breast cancer showed a significant influence of high NR1D1 expression on OS (P = 0.002) and DFS (P = 0.007) in patients with triple-negative breast cancer (TNBC) treated with chemotherapy.

Conclusions: High NR1D1 expression level had a favorable impact on OS and DFS in patients with TNBC treated with chemotherapy. NR1D1 should be investigated further as a possible prognostic marker in TNBC patients receiving chemotherapeutic treatment and as a target in the development of chemotherapeutic approaches to treating TNBC.

Keywords: Chemotherapy; DFS; NR1D1; OS; TNBC.

Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.
Stuart J Schnitt.
Mod Pathol, 2010 May 14; 23 Suppl 2. PMID: 20436504
Highly Cited. Review.
NR1D1 Recruitment to Sites of DNA Damage Inhibits Repair and Is Associated with Chemosensitivity of Breast Cancer.
Na-Lee Ka, Tae-Young Na, +6 authors, Mi-Ock Lee.
Cancer Res, 2017 Mar 03; 77(9). PMID: 28249904
NR1D1 enhances oxidative DNA damage by inhibiting PARP1 activity.
Na-Lee Ka, Tae-Young Na, Mi-Ock Lee.
Mol Cell Endocrinol, 2017 Jun 11; 454. PMID: 28599788
Triple negative tumours: a critical review.
J S Reis-Filho, A N J Tutt.
Histopathology, 2008 Jan 04; 52(1). PMID: 18171422
Highly Cited. Review.
Impact of REV-ERB alpha gene polymorphisms on obesity phenotypes in adult and adolescent samples.
L Goumidi, A Grechez, +11 authors, A Meirhaeghe.
Int J Obes (Lond), 2012 Jul 26; 37(5). PMID: 22828941
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2016 Oct 19; 13(11). PMID: 27184417    Free PMC article.
Highly Cited. Review.
Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma.
Lisa M Davis, Cole Harris, +10 authors, John Hozier.
J Mol Diagn, 2007 Jun 27; 9(3). PMID: 17591932    Free PMC article.
REV-ERB and ROR nuclear receptors as drug targets.
Douglas J Kojetin, Thomas P Burris.
Nat Rev Drug Discov, 2014 Mar 01; 13(3). PMID: 24577401    Free PMC article.
Highly Cited. Review.
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, +8 authors, Young Kee Shin.
PLoS One, 2018 Nov 22; 13(11). PMID: 30462685    Free PMC article.
REV-ERB ALPHA polymorphism is associated with obesity in the Spanish obese male population.
Elena G Ruano, Silvia Canivell, Elaine Vieira.
PLoS One, 2014 Aug 05; 9(8). PMID: 25089907    Free PMC article.
Functional genetic variation in the Rev-Erbα pathway and lithium response in the treatment of bipolar disorder.
M J McCarthy, C M Nievergelt, +3 authors, J R Kelsoe.
Genes Brain Behav, 2011 Jul 26; 10(8). PMID: 21781277    Free PMC article.
Nuclear receptor Rev-erbα: up, down, and all around.
Logan J Everett, Mitchell A Lazar.
Trends Endocrinol Metab, 2014 Jul 30; 25(11). PMID: 25066191    Free PMC article.
Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells.
Yongjun Wang, Douglas Kojetin, Thomas P Burris.
Biochem Pharmacol, 2015 Jun 16; 96(4). PMID: 26074263    Free PMC article.
DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer.
Brian M Alexander, Kam Sprott, +6 authors, Judy E Garber.
Clin Cancer Res, 2010 Dec 09; 16(23). PMID: 21138871    Free PMC article.
Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype.
P Karihtala, S Kauppila, U Puistola, A Jukkola-Vuorinen.
Br J Cancer, 2011 Nov 24; 106(2). PMID: 22108520    Free PMC article.
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
A A Rodriguez, A Makris, +11 authors, J C Chang.
Breast Cancer Res Treat, 2010 Jun 29; 123(1). PMID: 20582464
Triple negative breast cancers have a reduced expression of DNA repair genes.
Enilze Ribeiro, Monica Ganzinelli, +10 authors, Giovanna Damia.
PLoS One, 2013 Jul 05; 8(6). PMID: 23825533    Free PMC article.
MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Jinil Han, Yoon-La Choi, +11 authors, Young Kee Shin.
Breast Cancer Res Treat, 2017 Apr 15; 164(1). PMID: 28409241    Free PMC article.
Association study in a Sardinian sample between bipolar disorder and the nuclear receptor REV-ERBalpha gene, a critical component of the circadian clock system.
Giovanni Severino, Mirko Manchia, +5 authors, Maria Del Zompo.
Bipolar Disord, 2009 Mar 10; 11(2). PMID: 19267705
Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, +3 authors, Ahmedin Jemal.
CA Cancer J Clin, 2015 Feb 06; 65(2). PMID: 25651787
Highly Cited.
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Koei Chin, Sandy DeVries, +21 authors, Joe W Gray.
Cancer Cell, 2006 Dec 13; 10(6). PMID: 17157792
Highly Cited.
Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.
Yoon-La Choi, Ensel Oh, +12 authors, Young Kee Shin.
BMC Cancer, 2010 Sep 24; 10. PMID: 20860845    Free PMC article.
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, +4 authors, Jennifer A Pietenpol.
J Clin Invest, 2011 Jun 03; 121(7). PMID: 21633166    Free PMC article.
Highly Cited.
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Hiroko Masuda, Keith A Baggerly, +9 authors, Naoto T Ueno.
Clin Cancer Res, 2013 Aug 21; 19(19). PMID: 23948975    Free PMC article.
Highly Cited.
A Nomogram Based on Radiomics with Mammography Texture Analysis for the Prognostic Prediction in Patients with Triple-Negative Breast Cancer.
Xian Jiang, Xiuhe Zou, +2 authors, Chao Su.
Contrast Media Mol Imaging, 2020 Sep 15; 2020. PMID: 32922222    Free PMC article.